The American Diabetes Association also recommended that GLP1 receptor agonists should be one of the first combination drugs considered in the treatment of patients with type 2 diabetes who have developed atherosclerotic cardiovascular disease or high-risk indicators of Atherosclerotic cardiovascular disease.[13]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.